BioSpace News Archive

Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today provided a corporate update. “Since early this year, we have continued to make great strides in advancing our clinical assets, including initiation of a pilot phase 2 for our newest clinical therapeutic, AKST1210,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest. “Whils

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020, at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF). The webinar will feature a presentation by Marcus Mall, M.D., Professor and Director of the Department of Pediatric P

NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women’s Hospital, and NuMedii.

OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder and Chief Executive Officer of the Company will present its platform technology and discuss the potential utility of Asymmetric small interfering RNA (asiRNA), Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA) and GalNAc-asiRNA at the global Virtual RNAi-Based Therapeutics Summit on Wed

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter ended June 30, 2020 after market close on Monday, August 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: Thursday, July 30, 2020 1:30 p.m. Pac

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialt

First outside investment to accelerate on-demand access to world-leading, non-invasive brain recording technology

Virpax® Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the election of Vanila M. Singh, MD, MACM, to its Board of Directors.

Imbio, a healthcare technology company developing the leading suite of medical image analysis for pulmonary and cardiothoracic diseases, announced today that their FDA-cleared solutions will be available on the Nuance AI Marketplace,